Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-874 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen B | EXPERIMENTAL | One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein |
| Regimen C | EXPERIMENTAL | One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen D | EXPERIMENTAL | One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen E | EXPERIMENTAL | 700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein |
| Name | Type | Description |
|---|---|---|
| ABT-874 | DRUG | See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively. |
Inclusion Criteria: * Subjects must be healthy Exclusion Criteria: * Subjects who are not healthy, enrolled in another study, or who have received ABT-874 previously.
ABT-874 is an investigational small molecule drug developed by Abbott Laboratories. It has been studied in a Phase 1 clinical trial involving healthy adult volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed, and the compound remains in early-stage clinical development.
ABT-874 is made by Abbott Laboratories, which trades under the ticker ABT. Abbott is the developer responsible for the compound's clinical program. The drug has been evaluated in a single Phase 1 study conducted in the United States, and no other sponsors are listed for that trial.
ABT-874 is in Phase 1 clinical development. It has completed one Phase 1 trial, NCT00870948, which enrolled 75 healthy volunteers. There are currently no active trials for ABT-874. The drug is investigational and has not been approved for any indication.
ABT-874 has been studied in one clinical trial, NCT00870948, titled Phase 1 BA Study, Single Center With Healthy Volunteers. The trial was a completed Phase 1 study conducted in the United States with 75 enrolled participants. It was randomized and controlled, and enrolled healthy volunteers aged 18 years and older.
ABT-874 is not approved. It is an investigational drug that has completed a single Phase 1 clinical trial, NCT00870948, in healthy volunteers. No regulatory approval has been granted for any indication, and the compound remains in early-stage clinical development with no active trials currently listed.